Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Jasper Tromp^{1

2}, Mikhail N Kosiborod^{3

4

5

6}, Christiane E Angermann⁷, Sean P Collins⁸, John R Teerlink⁹, Piotr Ponikowski¹⁰, Jan Biegus¹⁰, João Pedro Ferreira¹¹, Michael E Nassif^{3

4}, Mitchell A Psotka¹², Martina Brueckmann^{13

14}, Jonathan P Blatchford¹⁵, Dominik Steubl^{16

17}, Adriaan A Voors¹⁸

Affiliations

¹ Saw Swee Hock School of Public Health, National University of Singapore & the National University Health System, Singapore, Singapore.
² Duke-NUS Medical School, Singapore, Singapore.
³ Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
⁴ School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.
⁵ George Institute for Global Health, Sydney, NSW, Australia.
⁶ University of New South Wales, Sydney, NSW, Australia.
⁷ Comprehensive Heart Failure Centre and Department of Medicine I (Cardiology), University and University Hospital of Würzburg, Würzburg, Germany.
⁸ Department of Emergency Medicine, Vanderbilt University Medical Center and Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA.
⁹ Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
¹⁰ Institute of Heart Diseases, Medical University, Wroclaw, Poland.
¹¹ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
¹² Inova Heart and Vascular Institute, Falls Church, VA, USA.
¹³ Boehringer Ingelheim International GmbH, Ingelheim, Germany.
¹⁴ First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
¹⁵ Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
¹⁶ Boehringer Ingelheim International, Ingelheim, Germany.
¹⁷ Department of Nephrology, Klinikum rechts der Isar, Faculty of Medicine, Technical University, Munich, Germany.
¹⁸ University of Groningen Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

PMID: 38572654
DOI: 10.1002/ejhf.3218

Free article

Randomized Controlled Trial

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Jasper Tromp et al. Eur J Heart Fail. 2024 Apr.

Free article

. 2024 Apr;26(4):963-970.

doi: 10.1002/ejhf.3218. Epub 2024 Apr 4.

Authors

Affiliations

¹ Saw Swee Hock School of Public Health, National University of Singapore & the National University Health System, Singapore, Singapore.
² Duke-NUS Medical School, Singapore, Singapore.
³ Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
⁴ School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.
⁵ George Institute for Global Health, Sydney, NSW, Australia.
⁶ University of New South Wales, Sydney, NSW, Australia.
⁷ Comprehensive Heart Failure Centre and Department of Medicine I (Cardiology), University and University Hospital of Würzburg, Würzburg, Germany.
⁸ Department of Emergency Medicine, Vanderbilt University Medical Center and Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA.
⁹ Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
¹⁰ Institute of Heart Diseases, Medical University, Wroclaw, Poland.
¹¹ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
¹² Inova Heart and Vascular Institute, Falls Church, VA, USA.
¹³ Boehringer Ingelheim International GmbH, Ingelheim, Germany.
¹⁴ First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
¹⁵ Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
¹⁶ Boehringer Ingelheim International, Ingelheim, Germany.
¹⁷ Department of Nephrology, Klinikum rechts der Isar, Faculty of Medicine, Technical University, Munich, Germany.
¹⁸ University of Groningen Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

PMID: 38572654
DOI: 10.1002/ejhf.3218

Abstract

Aim: The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left ventricular ejection fraction (LVEF).

Methods and results: A total of 530 patients hospitalized for acute de novo or decompensated HF were included irrespective of LVEF. For the present analysis, patients were classified as HF with reduced (HFrEF, LVEF ≤40%), mildly reduced (HFmrEF, LVEF 41-49%) or preserved (HFpEF, LVEF ≥50%) ejection fraction at baseline. The primary endpoint was a hierarchical outcome of death, worsening HF events (HFE) and quality of life over 90 days, assessed by the win ratio. Secondary endpoints included individual components of the primary endpoint and safety. Out of 523 patients with baseline data, 354 (67.7%) had HFrEF, 54 (10.3%) had HFmrEF and 115 (22.0%) had HFpEF. The clinical benefit (hierarchical composite of all-cause death, HFE and Kansas City Cardiomyopathy Questionnaire total symptom score) of empagliflozin at 90 days compared to placebo was consistent across LVEF categories (≤40%: win ratio 1.35 [95% confidence interval 1.04, 1.75]; 41-49%: win ratio 1.25 [0.66, 2.37)] and ≥50%: win ratio 1.40 [0.87, 2.23], p_interaction = 0.96) with a favourable safety profile. Results were consistent across individual components of the hierarchical primary endpoint.

Conclusion: The clinical benefit of empagliflozin proved consistent across LVEF categories in the EMPULSE trial. These results support early in-hospital initiation of empagliflozin regardless of LVEF.

Keywords: Acute heart failure; Left ventricular ejection fraction; SGLT2 inhibitor.

PubMed Disclaimer

References

1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical Practice Guidelines. Circulation 2022;145:e895–e1032. https://doi.org/10.1161/CIR.0000000000001063
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
1. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
1. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–1620. https://doi.org/10.1056/NEJMoa1908655
1. McMurray JJV, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: The CHARM‐Added trial. Lancet 2003;362:767–771. https://doi.org/10.1016/S0140‐6736(03)14283‐3

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Affiliations

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous